Saturday, November 29, 2014 1:05:53 AM
Purpose of the trial:
- To evaluate whether the Scaffold is safe and feasible for the treatment of complete functional spinal cord injury as determined by no degradation in paralysis level or sensory motor neurological function beyond that typically seen in the AIS A subject.
- To gather preliminary evidence of clinical effectiveness of the Scaffold, including improvement of ASIA Impairment Scale, sensory scores, motor scores, bladder and bowel function, neurological tests, and The Spinal Cord Independence Measure III.
http://clinicaltrials.gov/ct2/show/study/NCT02138110
As always, in my opinion only. Do your own due diligence!
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM